CD80/B7-1
Alpha Lifetech can provide CD80/B7-1 corresponding products, help each customer's research and development.
01
Introduction To CD80/B7-1
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. The introduction of CD80/B7-1 protein is a common target in medicine.
CD80, alias B7-1, belongs to the immunoglobulin superfamily, whose receptors include CD28, CD152 (CTLA 4), and PD-L1. CD80 expression was observed on activated B lymphocytes, activated T lymphocytes, human T-lymphocyte leukemia virus-1-positive T lymphocytes, monocytes stimulated with IFN- γ, and dendritic cells. Members of IgSF, each with 1-and V-like and C2-like regions, CD80 and CD86 share limited sequence homology in their extracellular domains.
Function of Target CD80/B7-1
CD80 or CD86 molecules on APC can provide a costimulatory signal for T cell activation CD80 is one of the costimulatory molecules required for T cell activation. It provides the co-stimulatory signals necessary for T cell activation and survival by interacting with its receptors CD28 or CTLA-4. This interaction is crucial in the initiation and maintenance of the T cell immune response. CD80 participates in immunoregulatory processes by regulating the activation state of T cells. Specifically, when binding to CD28, CD80 promotes T cell activation, while binding to CTLA-4 inhibits T cell activation and plays negative regulation. This balance of positive and negative regulation is essential for maintaining the homeostasis of the immune system.
CD80 is closely related to the occurrence and progression of multiple diseases. It has been used as a biomarker for certain diseases, such as type I diabetes, chronic obstructive pulmonary disease, demyelinating disease, relapsing-remitting multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, among others.
Gene Pathway of Target CD80/B7-1
Expressed CD80 and Neph 1 interact through their extracellular domain. This interaction implies the mechanism of slit diaphragm disruption and the possible potential to use small molecules that disrupt the CD80-Neph1 interaction as treatments for the nephrotic syndrome associated with CD80 upregulation. CD80 triggers the signaling process by binding to CD28 or CTLA-4 receptors on the T cell surface. This ligand-receptor binding leads to the activation and delivery of signaling molecules within T cells, ultimately affecting the T cell activation status and the immune response.
The binding of CD80 to CD28 promotes T cell activation, which is a positive control process, while the binding to CTLA-4 suppresses T cell activation for a negative control effect. This bidirectional control ensures the precision and moderation of the immune response.
Fig 1: B7-1 Gene Pathway. (Reference source: Chen R, Ganesan A, Okoye I, Arutyunova E, Elahi S, Lemieux MJ, Barakat K. Targeting B7-1 in immunotherapy. Med Res Rev. 2020 Mar;40(2):654-682.)
Alpha Lifetech Can Provide
At present, various drugs targeting CD80/B7-1 are constantly under development, and taking drugs alone or together with other products to treat diseases has become a new method and remarkable achievements have been made. CD80/B7-1 protein has shown important research value and application prospects in tumor biology, and drug research and development. With further research and technological advances, CD80/B7-1 protein products are also essential. Alpha Lifetech can provide CD80/B7-1 corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64668 | 50ug,100ug,500ug | |
| ALP64608 | ALP64608-Recombinant Human CD80/B7-1 Protein, His Tag | 50ug,100ug,500ug |
| ALP64604 | 50ug,100ug,500ug | |
| ALP64603 | 50ug,100ug,500ug | |
| ALP64602 | 50ug,100ug,500ug | |
| ALP64601 | 50ug,100ug,500ug | |
| ADT1262 | 100ug,1mg,5mg | |
Reference
[1] Sansom DM, Manzotti CN, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol. 2003 Jun;24(6):314-9
[2] Teh YM, Lim SK, Jusoh N, Osman K, Mualif SA. CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease. Biomed Res Int. 2021 Jan 6;2021:6671552.
[3] Darvish Z, Kheder RK, Faraj TA, Najmaldin SK, Mollazadeh S, Nosratabadi R, Esmaeili SA. A better understanding of the role of the CTLA-CD80/86 axis in the treatment of autoimmune diseases. Cell Biochem Funct. 2024 Jan;42(1):e3895.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102